Rachel Reyes-Bergano
Los Angeles, CANPI 1700226941
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $135,900 of the $158,140 with a category attached, or 85.9%. AbbVie accounts for 99.1% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $65,607 and has fallen 99.8% since, to $138 in 2025.
Across 231 payments — averaging $684.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$157K
- Galderma Laboratories, L.p.$1K
- Revance Therapeutics, Inc.$243
What the payments were for
- Consulting fees$7,5005%
- Speaking & faculty fees$135,90086%
- Travel & lodging$9,5846%
- Food & beverage$5,1303%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 178 | $156,785 |
| Galderma Laboratories, L.p. | 48 | $1,112 |
| Revance Therapeutics, Inc. | 5 | $243 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$63,031
- BOTOX COSMETIC$9,192
- KYBELLA$1,950
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.